Press releases and announcements

Gent, Belgium: March 5, 2015 - Fujirebio Europe today announced the release of the INNO-LiPA® HPV Genotyping Extra II assay for HPV type-specific patient monitoring and cervical cancer management. This CE-marked strip-based assay is available for automated testing on the Auto-LiPA™ 48 and AutoBlot 3000H platforms and the upcoming TENDIGO™ platform as well as for manual testing.

Gent, Belgium: October 1st 2014 - The LUMIPULSE G600II, a new member in the LUMIPULSE G series of chemiluminescent enzyme immunoassay (CLEIA) analyzers from Fujirebio, is now available on the European market. The LUMIPULSE G600 II is a compact and robust benchtop analyzer which features a constant throughput of 60 tests per hour.

Gent, Belgium: September 12 2014 - Fujirebio Europe today released a series of specialized assays for its chemiluminescent enzyme immunoassay (CLEIA) system, the LUMIPULSE® G1200, dedicated to the diagnosis and monitoring of HBV infection and the treatment of HBV patients. The HBV panel notably includes an entirely new tool in HBV testing, the Lumipulse® G HBcrAg, a unique serological marker (available as a Research Use Only test) correlated with cccDNA for improved monitoring of patients under treatment.

Gent, Belgium: August 13 2014 - Fujirebio Europe releases updates of its market-leading  INNO-LIA® Score immunoblot product range  and the associated LiRAS® for Infectious Diseases software for automated interpretation of results.

Ghent, Belgium: April 27 2014 - Fujirebio Europe announces the launch of its ProGRP assay to be used on the LUMIPULSE® G1200 chemiluminescent enzyme immunoassay (CLEIA) analyzer. The test is designed for the quantitative determination of ProGRP in human serum or plasma.

Gent, Belgium: April 4th 2014 - Fujirebio Europe today announced its intention to proceed with a reorganization in order to bring further focus and weight to the ongoing introduction of the LUMIPULSE® G1200 system on the European market, commenced in 2011. Fujirebio Europe has informed the Work’s Council in Gent about the estimated impact on employment and has communicated its intention to proceed for collective dismissal.

Fujirebio Europe announces the update of its entire range of INNOTEST® biomarkers for Alzheimer testing in routine. At the same occasion the company launches the INNOTEST® β-AMYLOID (1-40) test, an immunoassay kit for the quantification of β-Amyloid(1-40) in cerebrospinal fluid.

Ghent, Belgium: December 16 2013 - Fujirebio Europe announces the launch of its novel Lumipulse® G 25-OH Vitamin D assay to be used on the LUMIPULSE® G1200 chemiluminescent enzyme immunoassay (CLEIA) analyzer. The test is designed for the quantitative determination of 25-hydroxyvitamin D  in human serum or  plasma to be used in the assessment of Vitamin D sufficiency..

Gent, Belgium: November 13, 2013 - Fujirebio Europe (previously Innogenetics), a leading international healthcare company that conceives, develops, produces and markets high quality in vitro diagnostics (IVD) testing solutions worldwide, will be showcasing its LUMIPULSE® G1200, a fully automated chemiluminescent enzyme immunoassay (CLEIA) system, at the 58th edition of the Journées Internationales de Biologie (JIB) in the CNIT Paris la Défense, France, from November 13 to 15.

Gent, Belgium: October 23 2013 - Fujirebio Europe (previously Innogenetics), a leading international healthcare company that conceives, develops, produces and markets high quality in vitro diagnostics (IVD) testing solutions worldwide, will be presenting its LUMIPULSE® G1200, a fully automated chemiluminescent enzyme immunoassay (CLEIA) system, at the 10th Deutsche Vereinte Gesellschaft für Klinische Chemie und Laboratoriumsmedizin (DGKL) Congress in the Internationales Congress Center Dresden, Germany, from October 23rd to 26th.

Pages

CLOSE

You can change the country filter for contents in our website. You will then see local contact information and other information available for that country. Please choose your country in the list below:

Welcome to Fujirebio

It looks as if you are visiting from the United States. The content of this website is not destined for United States visitors.

If you continue your visit you confirm that you understand that not all of the products you will see listed are FDA cleared. FDA cleared products may not be cleared for all indications mentioned on this site. Product claims may differ from country to country based on regulations and approvals.

Please contact your country representative for further details.